2 years ago

Apollo Therapeutics Secures $226.5 Million in Series C Funding

  • Apollo Therapeutics, a UK-based biopharmaceutical company, has raised $226.5 million in Series C funding

  • The round was led by Patient Square Capital, with participation from new investors M&G plc and existing investor Rock Springs Capital

  • The company plans to use the funds to advance pipeline programs through clinical development and further fund its drug discovery and development activities

  • Apollo Therapeutics translates fundamental medical research into medicines through a portfolio-model, with a centralized management team and a diverse portfolio of therapeutic programs

  • The company currently partners with institutions like the University of Cambridge, Imperial College London, and King's College London.

      • ProblemHealthcare

      "Developing new medicines based on groundbreaking medical research is a complex and expensive process. Many promising discoveries never make it to patients because of lack of funding or expertise."

      Solution

      "Apollo Therapeutics provides a platform for translating fundamental medical research into medicines. They combine a centralized team of experts in pharmaceutical R&D, manufacturing, and commercialization with a diverse portfolio of therapeutic programs, each led by a dedicated asset leader. This model allows them to efficiently develop and commercialize new drugs."

      Covered on